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Background: Streptococcus pneumoniae infections are challeng-
ing sincepneumococcihavemore than90serotypesandemergence
of resistant strains has increased. Surveillance systems are essen-
tial for effective vaccine strategies and development of treatment
protocols. This study aimed to evaluate the serotype distribution
and antimicrobial susceptibility of S. pneumoniae causing invasive
pneumococcal disease in adults (>18 years).
Methods & Materials: S. pneumoniae strains were collected
from 14 different centers between 2005 and 2015. Pneumococcal
serogroup and serotype identiﬁcation was performed using stan-
dard conventional methods. Antibiotic susceptibility testing was
performed using E-test and interpreted according to the CLSI 2014
standards.
Results: S. pneumonia strains (n =346) were isolated from
blood (60.1%), bronchoalveolar lavage (19.7%), cerebrospinal ﬂuid
(11.0%), pleural ﬂuid (6.1%), and other body ﬂuids (3.1%). The most
common S. pneumoniae serotypeswere found as serotype 3 (13.0%),
19F (12.7%), 19A (6.1%), 14 (4.6%), and 6B (4.0%). Vaccine cover-
age rate was 27.4% for 7-valent pneumococcal conjugate vaccine
(PCV-7), 53.5% for PCV-13, and 62.3% for 23-valent pneumococcal
polysaccharide vaccine (PPV-23). For oral penicillin V, resistance
ratewas 21.7% and intermediate resistance ratewas 16.8%. For par-
enteral penicillin, 52.6% was resistant in strains isolated from CSF
(meningitis) and 0.6% was resistant and 5.8% was intermediate in
Table 1
Penicillin
V (oral)
Penicillin
parenteral
(non-meningitis)
Penicillin
parenteral
(meningitis)
Erythromycin
Coverage rates for
PCV-7 52.0% 60.0% 40.0% 55.6%
PCV-13 68.6% 90.0% 65.0% 76.7%
PPV-23 74.7% 85.0% 75.0% 79.7%
strains isolated from other specimens. For cefotaxime, 5.3% was
resistant and 18.4% was intermediate in strains isolated from CSF,
whereas 1.6% was resistant and 6.5% was intermediate in strains
isolated fromother specimens. Erythromycin resistancewas 28.6%.
No resistancewas detected tomoxiﬂoxacin but intermediate resis-
tance was 0.6%. Serotypes 19A and 19F exhibited higher rates of
penicillin and erythromycin resistances. Vaccine coverage rates for
non-susceptible (resistant and intermediate) strains are presented
in Table 1.
Conclusion: Since serotype distribution and antimicrobial sus-
ceptibility of clinical S. pneumoniae isolates may change in time
naturally also with medical interventions like antibiotic use and
vaccination, close monitoring is essential.
http://dx.doi.org/10.1016/j.ijid.2016.02.243
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Background: Brucellosis is a widespread zoonotic disease with
signiﬁcant economic and major public health problem. Failure of
response and relapse of brucellosis have reported with current
therapeutic regimens. Considering the high prevalence of brucel-
losis and recurrence rate of this disease in Iran, widespread and
inappropriate use of antibiotics could redound antibiotic resistance
among Brucella isolates in the community. The aim of this study
was to evaluate the antibiotic susceptibility pattern of Brucella iso-
lates by E-test method in Hamadan, west of Iran.
Methods & Materials: In this study, patients with clinical diag-
nosis of brucellosis who referred to Infectious Diseases Ward,
Sina hospital in Hamadan were studied between April 2013
and July 2014. Blood Specimens were collected for diagnosis of
brucellosis by BACTEC blood culture system. Antimicrobial sus-
ceptibility patterns of clinical isolates to gentamicin, streptomycin,
rifampin, doxycycline, ciproﬂoxacin, oﬂoxacin and trimethoprim-
sulfamethoxazole were performed by the E-test method. Then the
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CLSI zone size and Minimum Inhibitory Concentration interpretive
criteria were examined.
Results: One hundred forty-nine patients with brucellosis were
enrolled in this study. Culture of clinical samples were pos-
itive in 38.3%, of which, 91.2% were associated with positive
serological test. No signiﬁcant associations were found between
serological tests and culture method. All clinical isolates were
sensitive to doxycycline, streptomycin, gentamicin, ciproﬂoxacin
and moxiﬂoxacin, but intermediate sensitivity to rifampin and
trimethoprim-sulfamethoxazole were found in 35.08% and 3.5% of
isolates, respectively.
Conclusion: Because of the high frequency of intermediate sen-
sitivity to rifampin among brucella isolates, this drug should be
prescribed with caution. We recommend restricting the use of
rifampin for treatment of brucellosis except as an alternative drug
for special situations.
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Background: Carbapenem resistant Acinetobacter baumannii
complex and Pseudomonas aeruginosa are a major health problem
in our hospital, most of them being multidrug resistant strains
which are difﬁcult to treat with the current available antimicrobial
agents. This studywasundertaken toevaluate the in-vitroactivityof
fosfomycin as alternative treatment against carbapenem resistant
isolates.
Methods & Materials: Consecutive clinical isolates of car-
bapenem resistant Acinetobacter baumannii complex and Pseu-
domonas aeruginosa were collected over a 6 month study
period. Species identiﬁcation and antimicrobial susceptibility test-
ing was performed using Vitek-2 colorimetric compact systems
(BIOMERIUX, France). Fosfomycin testingwas initially done by disk
diffusion, thereafter the gradient diffusion method using the Etest
strips (LIOFILCHEM, Italy) was done for the veriﬁcation of themini-
mum inhibitory concentrations. Themodiﬁed Hodge test was done
to detect the presence of carbapenemases.
Results: A total of 133 carbapenems resistant clinical isolates
(72 (54.1%) Acinetobacter baumannii and 61 (45.9) Pseudomonas
aeruginosa), were collected from 125 patients. The majority of
patients were males between 30-60yrs and 72 (57.6%) were in the
ICUs, while 53 (42.4%) were in other wards. The specimens were
from Endo-Tracheal Aspirates (ETA) 80 (60.1%), 17 (12.8%) from
blood culture, 16 (12%) from wound swabs, tissues and effusions,
11 (8.3%) from CVP tips and 9 (6.8%) from urine. All isolates were
susceptible to fosfomycin in addition to colistin.
ANTIBIOTIC MIC range
ug/ml
Susceptible Intermediate Resistant
Colistin ≤ 2- ≥ 4 100% – –
Fosfomycin gradient
diffusion
≤ 64 - ≥
256
100% – –
Fosfomycin disk
diffusion
≤ 12 - ≥ 16 44.5% 47.2% 8.3%
Conclusion: In conclusion, treatment options for infections due
to carbapenem and multi-drugs resistant Acinetobacter bauman-
nii and Pseudomonas aeruginosa organisms are limited, therefore
fosfomycin may be considered as a therapeutic option for these
organisms.
http://dx.doi.org/10.1016/j.ijid.2016.02.245
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pncA mutations in mycobacterium tuberculosis
is a strong predictor of poor treatment outcome
in the therapy of multidrug resistant
tuberculosis
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Background: Despite the widely accepted association between
Pyrazinamide (PZA) resistance and mutations in pncA and rpsA
gene, it remainedunknownabout the clinical value of PZA genotypic
drug susceptibility testing(DST) for multidrug resistant tuberculosis
(MDR-TB) treatment, especially in the resource-limited area,where
the PZA phenotypic DST is difﬁcult to be implemented. Thus this
study was aimed at evaluating the role of PZA genotypic DST in
predicting poor treatment outcome in a MDR-TB treatment cohort.
Methods & Materials: This is a cohort study of 74 MDR-
TB patients who were identiﬁed and admitted to two Chinese
designated hospitals in 2010–2011. Demographic and clinical
information including treatment outcomes (sputum smear conver-
sion and treatment success) were retrieved from medical records.
Susceptibility to PZA and other 2nd line drugs were tested with the
MGIT 960 PZA kit.Mutations in pncA and rpsA geneswere identiﬁed
by DNA sequencing.
Results: Among 74 MDR-TB cases, 27 (36.5%) were pre-XDR TB
and 5(6.8%) were XDR-TB. 44.6% (33/74) had PZA resistance with
84.8% (28/33) mutations in pncA gene and 3.0% (3.0%) mutation
in rpsA gene. When comparing the treatment success reﬂected by
smear negativity after two months of standardized MDR-TB ther-
apy and a successful ﬁnal outcome it is clearly seen that a pncA
mutation predicted a less favorable response to treatment. A total
of 21 (75%) of the patients having a strain with such a mutation
were still smear positive after two months compared to 24 (53.3%)
in the groupwith strains showing the pncAwt sequence(OR: 0.511;
95%CI: 0.262–1.084). Similarly resultswere seen for ﬁnal treatment
success (registered after 24 months), were 9/26 cases and 29/41
cases respectively responded successfully based onWHOguideline
(OR: 0.107; 95%CI: 0.015–0.773).
